Fig. 2

The lncRNA-p21 is the key factor to promote the NED after Enz treatment and maintain the NE cell characteristics. a Overexpressing lncRNA-p21 in C4-2 cells for NE markers analysis by qPCR. b Overexpressing lncRNA-p21 in C4-2 cells for NE markers analysis by WB. c The NE markers in NE1.8 cells after knocking down lncRNA-p21 were determined by qPCR. d The NE markers in NCI-H660 cells after knocking down lncRNA-p21 were determined by qPCR. e The lncRNA-p21 was knocked down in NE1.8 cells and cell viability was analyzed by MTT. f The lncRNA-p21 was knocked down in NCI-H660 cells and cell viability was analyzed by MTT. g Cell morphology of pLKO and sh-lncRNA-p21 C4-2 cells after Enz treatment. (Scale bar = 20 μm) h Knockdown of lncRNA-p21 decreased the Enz-induced NE marker protein levels. The C4-2 pLKO control and sh-lncRNA-p21 cells were treated with Enz for 6 days, and then the NE markers analyzed by WB. i Knockdown of lncRNA-p21 decreased the Enz-induced mRNA of NE markers. The C4-2 pLKO control and sh-lncRNA-p21 cells were treated with Enz for 6 days, and then the NE markers determined by qPCR. j Images of 22RV1-pWPI and 22RV1-lncRNA-p21 xenograft tumors. k The IHC staining of the NE markers in 22RV1-pWPI and 22RV1-lncRNA-p21 xenograft tumors. l The correlation of expressions of LncRNA-p21 and NE markers (NSE, SYP, ChgA) in human prostate cancer samples. (n = 34). For c–f, i, l, the data are presented as mean ± SD, **p < 0.005. by t-test for two groups or ANOVA for more than two groups